Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment

Alan O., Telli T., Basoğlu T., Arikan R., Demircan N., Ercelep O., ...Daha Fazla

CLINICAL NEUROLOGY AND NEUROSURGERY, cilt.196, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 196
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.clineuro.2020.105976
  • Dergi Adı: CLINICAL NEUROLOGY AND NEUROSURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CAB Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: glioblastoma, Glasgow prognostic score, high grade gliomas, ATRX status, overall survival, CENTRAL-NERVOUS-SYSTEM, SINGLE-AGENT BEVACIZUMAB, ACUTE-PHASE RESPONSE, SERUM-ALBUMIN LEVELS, INFLAMMATORY RESPONSE, SURVIVAL, CHEMOTHERAPY, TRIAL, IL-6, GPS
  • Marmara Üniversitesi Adresli: Evet

Özet

Objectives: Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor. We aimed to evaluate the prognostic value of modified Glasgow Prognostic Score (mGPS), which is combination of C-reactive protein (CRP) and albumin, in recurrent high-grade glioma patients treated with systemic treatment.